Gemini Therapeutics, Inc. – NASDAQ:GMTX
Gemini Therapeutics stock price today
$1.35
-20.35
-93.78%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Gemini Therapeutics stock price monthly change
+1300.64%
month
Gemini Therapeutics stock price quarterly change
+1099.45%
quarter
Gemini Therapeutics stock price yearly change
+1060.96%
year
Gemini Therapeutics key metrics
Market Cap | 25.49M |
Enterprise value | N/A |
P/E | -1.34 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.55 |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGemini Therapeutics stock price history
Gemini Therapeutics stock forecast
Gemini Therapeutics financial statements
| 2022-08-11 | -0.2 | -0.16 |
|---|
Gemini Therapeutics alternative data
| Aug 2023 | 24 |
|---|---|
| Sep 2023 | 24 |
| Oct 2023 | 24 |
| Nov 2023 | 24 |
| Dec 2023 | 24 |
| Jan 2024 | 24 |
| Feb 2024 | 24 |
| Mar 2024 | 24 |
| Apr 2024 | 24 |
| May 2024 | 24 |
| Jun 2024 | 24 |
| Jul 2024 | 24 |
| Dec 2024 | 24 |
Gemini Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 652175 | 0 |
| Jun 2023 | 204081 | 1279580 |
| Aug 2023 | 0 | 277393 |
| Sep 2023 | 0 | 358449 |
| Nov 2023 | 0 | 15000 |
| Dec 2023 | 0 | 1248723 |
| Insider | Compensation |
|---|---|
Mr. Jason Patrick Meyenburg M.B.A., M.D. (1977) Chief Executive Officer, Pres & Director | $530,290 |
Monday, 21 November 2022 | ||
| 7 Short-Squeeze Stocks for Bold Contrarians to Consider | InvestorPlace | |
Tuesday, 12 April 2022 | ||
| Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? | Zacks Investment Research | |
Wednesday, 15 December 2021 | ||
| Gemini Therapeutics Shares Jump As HC Wainwright Sees Over 500% Upside | Benzinga | |
Thursday, 11 November 2021 | ||
| Gemini Therapeutics to Participate in Upcoming Investor Conferences | Business Wire | |
Wednesday, 10 November 2021 | ||
| Should You Buy Gemini Therapeutics (GMTX) Ahead of Earnings? | Zacks Investment Research | |
Wednesday, 6 October 2021 | ||
| GMTX Stock: Why It Fell This Week | Pulse2 | |
Friday, 10 September 2021 | ||
| Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics | Business Wire | |
Monday, 30 August 2021 | ||
| Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock? | Zacks Investment Research |
-
What's the price of Gemini Therapeutics stock today?
One share of Gemini Therapeutics stock can currently be purchased for approximately $1.35.
-
When is Gemini Therapeutics's next earnings date?
Unfortunately, Gemini Therapeutics's (GMTX) next earnings date is currently unknown.
-
Does Gemini Therapeutics pay dividends?
No, Gemini Therapeutics does not pay dividends.
-
How much money does Gemini Therapeutics make?
Gemini Therapeutics has a market capitalization of 25.49M.
-
What is Gemini Therapeutics's stock symbol?
Gemini Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GMTX".
-
What is Gemini Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Gemini Therapeutics?
Shares of Gemini Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Gemini Therapeutics's key executives?
Gemini Therapeutics's management team includes the following people:
- Mr. Jason Patrick Meyenburg M.B.A., M.D. Chief Executive Officer, Pres & Director(age: 48, pay: $530,290)
-
How many employees does Gemini Therapeutics have?
As Dec 2024, Gemini Therapeutics employs 24 workers.
-
When Gemini Therapeutics went public?
Gemini Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 12 Aug 2020.
-
What is Gemini Therapeutics's official website?
The official website for Gemini Therapeutics is geminitherapeutics.com.
-
Where are Gemini Therapeutics's headquarters?
Gemini Therapeutics is headquartered at 300 One Kendall Square, Cambridge, MA.
-
How can i contact Gemini Therapeutics?
Gemini Therapeutics's mailing address is 300 One Kendall Square, Cambridge, MA and company can be reached via phone at +212 6001902.
Gemini Therapeutics company profile:
Gemini Therapeutics, Inc.
geminitherapeutics.comExchange:
NASDAQ
Full time employees:
24
Industry:
Biotechnology
Sector:
Healthcare
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
300 One Kendall Square
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001816736
ISIN: US36870G1058
CUSIP: 36870G105
